IL283414A - Methods of treating conditions related to the s1p1 receptor - Google Patents

Methods of treating conditions related to the s1p1 receptor

Info

Publication number
IL283414A
IL283414A IL283414A IL28341421A IL283414A IL 283414 A IL283414 A IL 283414A IL 283414 A IL283414 A IL 283414A IL 28341421 A IL28341421 A IL 28341421A IL 283414 A IL283414 A IL 283414A
Authority
IL
Israel
Prior art keywords
receptor
methods
conditions associated
treating conditions
treating
Prior art date
Application number
IL283414A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL283414A publication Critical patent/IL283414A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
IL283414A 2018-11-30 2021-05-25 Methods of treating conditions related to the s1p1 receptor IL283414A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773936P 2018-11-30 2018-11-30
US201962850464P 2019-05-20 2019-05-20
PCT/US2019/063413 WO2020112880A1 (en) 2018-11-30 2019-11-26 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
IL283414A true IL283414A (en) 2021-07-29

Family

ID=68966033

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283414A IL283414A (en) 2018-11-30 2021-05-25 Methods of treating conditions related to the s1p1 receptor

Country Status (9)

Country Link
US (1) US20220023258A1 (enExample)
EP (1) EP3886841A1 (enExample)
JP (2) JP2022511788A (enExample)
KR (1) KR102824401B1 (enExample)
CN (2) CN118649163A (enExample)
AU (1) AU2019387212A1 (enExample)
CA (1) CA3120706A1 (enExample)
IL (1) IL283414A (enExample)
WO (1) WO2020112880A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2326621T (pt) * 2008-07-23 2016-09-12 Arena Pharm Inc Derivados de ácido 1,2,3,4-tetrahidrociclopenta[b]indol-3-il) acético substituídos úteis no tratamento de distúrbios autoimunes e inflamatórios
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
CN106063787A (zh) * 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP2017515896A (ja) * 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
CA3000569A1 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Also Published As

Publication number Publication date
KR20210098487A (ko) 2021-08-10
US20220023258A1 (en) 2022-01-27
KR102824401B1 (ko) 2025-06-25
CN118649163A (zh) 2024-09-17
CA3120706A1 (en) 2020-06-04
WO2020112880A1 (en) 2020-06-04
EP3886841A1 (en) 2021-10-06
AU2019387212A1 (en) 2021-06-24
JP2022511788A (ja) 2022-02-01
CN113226307A (zh) 2021-08-06
JP2025024035A (ja) 2025-02-19

Similar Documents

Publication Publication Date Title
IL280913A (en) Novel methods
EP3890716A4 (en) POLYTHERAPIES
IL283414A (en) Methods of treating conditions related to the s1p1 receptor
EP3568979A4 (en) INTRA-PREDICTION WITH MULTIPLE REFERENCE LINES
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
PL3283110T3 (pl) Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
DK3242666T5 (da) Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
DK3849537T3 (da) Kombinationsterapier
EP3763567A4 (en) SEAT
DK3737403T3 (da) Modificerede adenovira
IL284114A (en) Methods of treating conditions related to the s1p1 receptor
IL279180A (en) Methods of treating conditions related to the S1P1 receptor
EP3876776C0 (en) CONNECTOR
EP3843832C0 (en) NEUROMODULATION SYSTEM
EP3792200A4 (en) TANK-CONTAINER
IL281594A (en) Anti-klrg1 antibodies
IL272163A (en) Methods of treating myelodysplastic syndrome
EP3899155A4 (en) IMPROVED CONNECTOR
EP3813610A4 (en) Locking mechanism
EP3799000A4 (en) Unlocking system
CL2018000755S1 (es) Cerradura
EP3811824A4 (en) SEAT
DK3617431T3 (da) Lås
EP3843748C0 (en) COMBINATION THERAPY
EP3805628A4 (en) NEW LED FILAMENT